Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2010 - 2026)

Lineage Cell Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 1529.52% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was $665000.0, a 154.87% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 235.1% from the prior year.
• Change in Accured Expenses declined to -$1.7 million in Q1 2026 per LCTX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.5 million in Q4 2025 and bottomed at -$18.9 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$354000.0 (2025), against an average of -$1.3 million.
• Across the five-year window, Change in Accured Expenses sank 1733.66% in 2022 and surged 2435.05% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.1 million in 2022, then soared by 202.83% to $1.2 million in 2023, then tumbled by 91.65% to $97000.0 in 2024, then jumped by 2435.05% to $2.5 million in 2025, then plunged by 169.58% to -$1.7 million in 2026.
• Per Business Quant, the three latest LCTX Change in Accured Expenses figures stand at -$1.7 million (Q1 2026), $2.5 million (Q4 2025), and $271000.0 (Q3 2025).